All Stories

  1. Impact of the 2008 US FDA warnings for fluoroquinolone use in veterans ≥ 60 years of age with lung cancer

    Article • INNOVATIONS in pharmacy, March 2026, University of Minnesota

    Ronald Hall

  2. Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Partial‐ and Full‐Thickness Skin Burns

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, November 2025, Wiley

    Ronald Hall

  3. Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer

    Article • Journal of Oncology Pharmacy Practice, March 2025, SAGE Publications

    Ronald Hall

  4. Impact of PCV13 and PPSV23 Vaccination on Invasive Pneumococcal Disease in Adults with Treated Rheumatoid Arthritis: A Population-Based Study

    Article • Microorganisms, October 2024, MDPI AG

    Ronald Hall

  5. A Retrospective Analysis of Intravenous Push versus Extended Infusion Meropenem in Critically Ill Patients

    Article • Antibiotics, September 2024, MDPI AG

    Ronald Hall

  6. Optimizing anidulafungin exposure across a wide adult body size range

    Article • Antimicrobial Agents and Chemotherapy, November 2023, ASM Journals

    Ronald Hall

  7. Insufficient Representation of Patients With Obesity in Randomized Controlled Trials Evaluating the Efficacy and Safety of Antimicrobials for Treatment of Skin and Skin Structure Infections: A Scoping Review

    Article • Open Forum Infectious Diseases, March 2023, Oxford University Press (OUP)

    Ronald Hall

  8. Evaluation of Dose Requirements Using Weight-Based versus Non-Weight-Based Dosing of Norepinephrine to Achieve a Goal Mean Arterial Pressure in Patients with Septic Shock

    Article • Journal of Clinical Medicine, February 2023, MDPI AG

    Ronald Hall

  9. Evaluation of Scholarship Motivators and Barriers for Non-Tenure-Track Faculty in a Department of Pharmacy Practice

    Article • Pharmacy, February 2023, MDPI AG

    Ronald Hall

  10. Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

    Article • Microorganisms, February 2023, MDPI AG

    Ronald Hall

  11. How Well Are Pharmacists Represented in National Institutes of Health R01 Funding to United States Schools of Pharmacy?

    Article • Pharmacy, November 2022, MDPI AG

    Ronald Hall

  12. The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) Database

    Article • Antibiotics, October 2022, MDPI AG

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  13. Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care

    Article • Journal of the American Medical Directors Association, June 2022, Elsevier

    Ronald Hall

  14. The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

    Article • Antibiotics, February 2022, MDPI AG

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  15. Potential Excess Intravenous Antibiotic Therapy in the Setting of Gram-Negative Bacteremia

    Article • Pharmacy, August 2021, MDPI AG

    Ronald Hall

  16. Efficacy and benefits of mock residency interviews

    Article • Currents in Pharmacy Teaching and Learning, August 2021, Elsevier

    Ronald Hall

  17. Pharmacists Without Access to the EHR: Practicing with One Hand Tied Behind Our Backs

    Article • INNOVATIONS in pharmacy, July 2021, University of Minnesota

    Ronald Hall

  18. Effects of Propofol on Hemodynamic Profile in Adults Receiving Targeted Temperature Management

    Article • Hospital Pharmacy, July 2021, SAGE Publications

    Ronald Hall

  19. Do the types and routes of proton pump inhibitor treatments affect clostridium difficile in ICU patients? A retrospective cohort study

    Article • Expert Review of Clinical Pharmacology, February 2021, Taylor & Francis

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  20. Characterization and compensation of inhomogeneity artifact in spiral hyperpolarized13C imaging of the human heart

    Article • Magnetic Resonance in Medicine, February 2021, Wiley

    Ronald Hall

  21. Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making

    Article • Neuro-Oncology Advances, January 2021, Oxford University Press (OUP)

    Ronald Hall

  22. Effect of Doxorubicin on Myocardial Bicarbonate Production From Pyruvate Dehydrogenase in Women With Breast Cancer

    Article • Circulation Research, December 2020, Wolters Kluwer Health

    Ronald Hall

  23. Vancomycin Area Under the Curve‐guided Dosing and Monitoring: “Is the Juice Worth the Squeeze”?

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2020, Wiley

    Ronald Hall

  24. Imaging Acute Metabolic Changes in Patients with Mild Traumatic Brain Injury Using Hyperpolarized [1-13C]Pyruvate

    Article • iScience, December 2020, Elsevier

    Ronald Hall

  25. Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine

    Article • Journal of Chromatography B, November 2020, Elsevier

    Ronald Hall

  26. Impact of Neostigmine and Sugammadex on Time to Leaving the Operating Room in a Community Hospital

    Article • INNOVATIONS in pharmacy, August 2020, University of Minnesota

    Ronald Hall

  27. Appropriateness of Fluoroquinolone Prescribing in the Long‐Term Care Setting

    Article • Journal of the American Geriatrics Society, January 2020, Wiley

    Ronald Hall

  28. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin–tazobactam and vancomycin

    Article • American Journal of Health-System Pharmacy, August 2019, Oxford University Press (OUP)

    Ronald Hall

  29. A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults

    Article • Mental Health Clinician, July 2019, College of Psychiatric and Neurologic Pharmacists (CPNP)

    Ronald Hall

  30. Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity

    Article • Journal of Clinical Medicine, June 2019, MDPI AG

    Ronald Hall

  31. Impact of piperacillin/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia

    Article • International Journal of Antimicrobial Agents, March 2019, Elsevier

    Ronald Hall

  32. An evaluation of tedizolid for the treatment of MRSA infections

    Article • Expert Opinion on Pharmacotherapy, September 2018, Taylor & Francis

    Ronald Hall

  33. Impact of total body weight on acute kidney injury in patients with gram-negative bacteremia

    Article • Expert Review of Clinical Pharmacology, May 2018, Taylor & Francis

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  34. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)

    Article • Expert Review of Clinical Pharmacology, December 2017, Taylor & Francis

    Ronald Hall

  35. Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2017, Wiley

    Dr Tawanda Gumbo, Ronald Hall

  36. Impact of total body weight on 30-day mortality in patients with gram-negative bacteremia

    Article • Expert Review of Anti-infective Therapy, May 2017, Taylor & Francis

    Ronald Hall, Andrew Faust, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  37. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)

    Article • Expert Review of Clinical Pharmacology, March 2017, Taylor & Francis

    Ronald Hall

  38. A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections

    Article • Annals of Clinical Microbiology and Antimicrobials, November 2016, Springer Science + Business Media

    Ronald Hall

  39. Fractal Geometry‐Based Decrease in Trimethoprim‐Sulfamethoxazole Concentrations in Overweight and Obese People

    Article • CPT Pharmacometrics & Systems Pharmacology, November 2016, Wiley

    Ronald Hall

  40. Predictors of community-associated Staphylococcus aureus, methicillin-resistant and methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in primary-care settings

    Article • Epidemiology and Infection, August 2016, Cambridge University Press

    Ronald Hall

  41. Dosing of antifungal agents in obese people

    Article • Expert Review of Anti-infective Therapy, December 2015, Taylor & Francis

    Ronald Hall

  42. Low-Molecular-Weight Heparin Prophylaxis Dosing

    Article • Journal of Pharmacy Technology, November 2015, SAGE Publications

    Ronald Hall

  43. Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World

    Article • Current Pharmaceutical Design, October 2015, Bentham Science Publishers

    Ronald Hall

  44. Treatment of community-acquired pneumonia

    Article • Expert Review of Anti-infective Therapy, June 2015, Taylor & Francis

    Ronald Hall

  45. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections

    Article • Infection and Drug Resistance, April 2015, Taylor & Francis

    Ronald Hall

  46. In silico‐derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos

    Article • Clinical Pharmacology & Therapeutics, December 2014, Wiley

    Ronald Hall

  47. Empiric Weight-Based Vancomycin in Intensive Care Unit Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia

    Article • The American Journal of the Medical Sciences, November 2014, Elsevier

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  48. Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistantStaphylococcus aureusbacteraemia

    Article • Journal of Clinical Pharmacy and Therapeutics, September 2014, Wiley

    M.D; Ph.D; FIDSA Carlos Alvarez-Moreno, Ronald Hall

  49. Dosing of antibacterial agents in obese adults: does one size fit all?

    Article • Expert Review of Anti-infective Therapy, May 2014, Taylor & Francis

    Ronald Hall

  50. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis

    Article • BMC Infectious Diseases, March 2014, Springer Science + Business Media

    Ronald Hall

  51. Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents

    Article • Annals of Pharmacotherapy, November 2013, SAGE Publications

    Ronald Hall

  52. Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

    Article • Antimicrobial Agents and Chemotherapy, March 2013, ASM Journals

    Ronald Hall

  53. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

    Article • BMC Pharmacology and Toxicology, February 2013, Springer Science + Business Media

    Ronald Hall, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  54. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study

    Article • BMC Infectious Diseases, April 2012, Springer Science + Business Media

    Ronald Hall, M.D; Ph.D; FIDSA Carlos Alvarez-Moreno

  55. Ethambutol Pharmacokinetic Variability Is Linked to Body Mass in Overweight, Obese, and Extremely Obese People

    Article • Antimicrobial Agents and Chemotherapy, December 2011, ASM Journals

    Ronald Hall

  56. Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People

    Article • Antimicrobial Agents and Chemotherapy, August 2011, ASM Journals

    Ronald Hall

  57. Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter ?

    Article • Annals of Pharmacotherapy, February 2011, SAGE Publications

    Ronald Hall

  58. Evaluation of Chemotherapy-Induced Severe Myelosuppression Incidence in Obese Patients With Capped Dosing

    Article • Journal of Oncology Practice, January 2011, American Society of Clinical Oncology (ASCO)

    Ronald Hall

  59. Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind

    Article • Journal of Intensive Care Medicine, July 2010, SAGE Publications

    Ronald Hall

  60. Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?

    Article • The American Journal of Medicine, February 2010, Elsevier

    Ronald Hall

  61. Corrigendum

    Article • Expert Review of Anti-infective Therapy, February 2010, Taylor & Francis

    Ronald Hall

  62. Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections

    Article • Expert Review of Anti-infective Therapy, January 2010, Taylor & Francis

    Ronald Hall

  63. Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2009, Wiley

    Ronald Hall

  64. A Formalized Teaching, Practice, and Research Partnership with the Veterans Affairs North Texas Health Care System: A Model for Advancing Academic Partnerships

    Article • American Journal of Pharmaceutical Education, September 2009, Elsevier

    Ronald Hall

  65. Acute elevation of triglycerides after initiation of fosamprinavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia

    Article • Journal of Clinical Lipidology, October 2008, Elsevier

    Ronald Hall

  66. Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

    Article • Journal of Cardiovascular Pharmacology, June 2008, Wolters Kluwer Health

    Ronald Hall

  67. Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity

    Article • The American Journal of Medicine, June 2008, Elsevier

    Ronald Hall

  68. Impact of Inadequate Empiric Antimicrobial Therapy on Clinical Outcomes of Patients With Escherichia coli or Klebsiella Species Bacteremia

    Article • Journal of Pharmacy Practice, October 2007, SAGE Publications

    Ronald Hall

  69. Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

    Article • CHEST Journal, September 2007, Elsevier

    Ronald Hall

  70. Simulated Comparison of the Pharmacodynamics of Ciprofloxacin and Levofloxacin Against Pseudomonas aeruginosa Using Pharmacokinetic Data from Healthy Volunteers and 2002 Minimum Inhibitory Concentration Data

    Article • Clinical Therapeutics, July 2007, Elsevier

    Ronald Hall

  71. Gatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature

    Article • Journal of Pharmacy Practice, February 2007, SAGE Publications

    Dr Krystal L Edwards, Ronald Hall

  72. Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus

    Article • Annals of Pharmacotherapy, February 2007, SAGE Publications

    Ronald Hall

  73. Atazanavir for the Treatment of Human Immunodeficiency Virus Infection

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2004, Wiley

    Ronald Hall

  74. In vitro activity of parenteral β-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum β-lactamase producing Klebsiella pneumoniae

    Article • International Journal of Antimicrobial Agents, July 2004, Elsevier

    Ronald Hall

  75. Retrospective Study of Clinical Outcomes with Extended‐Spectrum β‐Lactamases—A Different Interpretation

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, June 2004, Wiley

    Ronald Hall

  76. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae

    Article • Diagnostic Microbiology and Infectious Disease, May 2004, Elsevier

    Ronald Hall

  77. Clinical and Microbiologic Analysis of a Hospital's Extended‐Spectrum β‐Lactamase‐Producing Isolates Over a 2‐Year Period

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, October 2003, Wiley

    Ronald Hall

  78. In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa

    Article • Diagnostic Microbiology and Infectious Disease, June 2003, Elsevier

    Ronald Hall